



## Press Release

### **Value-Added Medicine from STADA – Launch of Anti-Cancer Drug Bortezomib STADA as Ready-to-Use Solution**

- STADA's Bortezomib can be launched in 14 European countries as the first generic through the use of an innovative ready-to-use injection solution
- A ready-to-use solution for injection is easier for pharmacists to process, giving it an advantage over the originator product
- CEO Peter Goldschmidt: "The product launch of Bortezomib STADA is one of the most important international launches in STADA's history and has clear product added value."

Bad Vilbel, May 14, 2019 – STADA Group is launching the anti-cancer drug Bortezomib STADA for treating patients with progressive multiple myeloma in 14 European countries. Bortezomib STADA is a ready-to-use solution for injecting Bortezomib, an anti-cancer drug that is marketed by the originator under the brand name Velcade®.

Unlike the originator product, the STADA version of the medication is offered as a ready-to-use solution for injection, which means that the active ingredient does not need to be dissolved before being used. This allows pharmacists to skip part of the preparation process, simplifies their work and increases safety in dosage and handling. The medication is then injected by a physician. The use of a ready-to-use injection solution allows STADA to launch the product in 14 European countries immediately. If the same formulation as that of the originator had been used, a freeze-dried powder (lyophilisate), this may not have been possible before 2022. CEO Peter Goldschmidt commented, "This product launch is internationally one of the most important in STADA's history. With the development of Bortezomib STADA ready-to-use, we have managed to give patients early access to an affordable alternative to the originator product. At the same time, we are offering pharmacists an additional benefit since the medication is offered not as a powder, as it was previously, but in the form of a ready-to-use solution for injection. This is easier and more reliable to process."

STADA is launching Bortezomib in Belgium, Denmark, Germany, Finland, France, the UK, Ireland, Italy, Luxembourg, the Netherlands, Austria, Portugal, Spain and Sweden.

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au



#### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription Consumer Health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 130 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: [ir@stada.de](mailto:ir@stada.de)

Or visit us on the Internet at [www.stada.com/investor-relations](http://www.stada.com/investor-relations)

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au